RxDoctor Payments Data

Lauren Obrien, MD

Family Medicine · Washington, PANPI 1043447642

Payments from drug & device makers

$408in general payments, 2019–2025

Across 17 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Biopharmaceuticals, Inc$124
  • Phathom Pharmaceuticals, Inc.$88
  • Novo Nordisk$40
  • Otsuka America Pharmaceutical, Inc.$39
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$34
  • Edwards Lifesciences$23
  • plus $59 from 4 others

What the payments were for

  • Food & beverage$408100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$408 in reported general payments places this provider in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$17,814
Medicare patients
100
Services billed
209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$26,254
OzempicSemaglutide20$21,271
JardianceEmpagliflozin22$19,535
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,804
EntrestoSacubitril/Valsartan12$9,644
AbrysvoRsv Vacc, Pref A And Pref B/Pf11$3,477
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$2,156
SynthroidLevothyroxine Sodium15$1,336
Atorvastatin Calcium163$1,133
Pantoprazole Sodium87$1,051
Boostrix TdapDiphth,pertuss(Acell),tet Vac14$954
Levothyroxine Sodium75$883
Lisinopril122$843
Simvastatin84$833
Gabapentin49$819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$40$21,27120 claims
AbbVieSynthroid$13$1,33615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Washington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →